• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
NEU
Click for more information
1.04% $19.89

NEUREN PHARMACEUTICALS LIMITED - News & Media

Market Cap $2.540B  ! watchlist Created with Sketch. Add to my watchlist
Healthcare

Neuren Pharmaceuticals Limited is an Australia-based biopharmaceutical company developing... Neuren Pharmaceuticals Limited is an Australia-based biopharmaceutical company developing therapies for neurodevelopmental disorders. The Company is developing new drug therapies to treat multiple serious neurological disorders that emerge in early childhood and have no or limited approved treatment options. The Company’s product DAYBUE (trofinetide) is used to treat Rett syndrome in adults and pediatric patients two years of age and older. The United States (US) Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have both granted orphan drug designation to the Company for trofinetide in Fragile X syndrome. Its second product NNZ-2591 is in phase II clinical trials in Phelan-McDermid syndrome, Angelman syndrome, Pitt Hopkins syndrome and Prader-Willi syndrome. The Company has granted an exclusive worldwide license to Acadia Pharmaceuticals Inc. for the development and commercialization of NNZ-259 for Rett syndrome and Fragile X syndrome.More

Articles & Videos

Neuren flags Q4 DAYBUE sales of US$87m but shares take nosedive right out the gate

Neuren (ASX:NEU) shares were down -12% out the gate on Wednesday per CBOE live pricing, even as the stock flagged US$87.1M in sales of its flagship drug DAYBUE in Q4 of 2023.

28 Feb 2024 10:26 (AEDT)

"Things are worse": Neuren Pharmaceuticals shares sink as wonder drug questioned

ASX-listed Neuren Pharmaceuticals' (ASX:NEU) shares were down more than 13 per cent in lunchtime trades as the company is caught up in a short seller stoush.

16 Feb 2024 13:52 (AEDT)

Neuren Pharmaceuticals completes enrolment in Angelman syndrome phase two trial

Neuren Pharmaceuticals (ASX:NEU) has entered the last phase of screening for its phase two clinical trial using NNZ-2591 in AS, with all subjects now enrolled.

20 Dec 2023 10:51 (AEDT)

Neuren Pharma Reports positive results in phase 2 trial for NNZ-2591

Neuren Pharmaceuticals has unveiled findings from its Phase 2 clinical trial of NNZ-2591 in treating Phelan-McDermid syndrome

18 Dec 2023 10:31 (AEDT)

Neuren Pharmaceuticals (ASX:NEU) expands global partnership with Acadia

Neuren (ASX:NEU) has announced its North American exclusive licence for the drug trofinetide has been expanded to a global licence.

14 Jul 2023 11:57 (AEST)

Neuren Pharamceuticals (ASX:NEU) opens first US site for Prader-Willi trial

Neuren Pharmaceuticals (ASX:NEU) has opened the first site in the United States for its phase two clinical trial in Prader-Willi syndrome.

28 Jun 2023 15:57 (AEST)

Neuren Pharmaceuticals (ASX:NEU) partner drug approved as first treatment for Rett syndrome

Neuren Pharmaceuticals' (ASX:NEU) North American partner, Acadia Pharmaceuticals, has had its treatment for Rett syndrome approved by the US Food and Drug Administration.

13 Mar 2023 10:53 (AEDT)

Neuren Pharmaceuticals (ASX:NEU) receives FDA approval for Prader-Willi syndrome phase II trial

The US FDA has given Neuren Pharmaceuticals (ASX:NEU) the green light for a clinical trial testing its drug NNZ-2591 on children.

23 Jan 2023 11:16 (AEDT)



(20min delay)
Last
$19.89 		Change
-0.210(1.04%) 		Mkt cap ! $2.540B
Open High Low Value Volume
$20.17 $20.17 $19.66 $1.438M 72.28K

Buyers (Bids)

No. Vol. Price($)
3 108 $19.89
 

Sellers (Offers)

Price($) Vol. No.
$19.90 267 10
View Market Depth
Last trade - 11.57am 03/07/2024 (20 minute delay) ?
Last
$19.91 		  Change
-0.210 ( 0.95 %)
Open High Low Volume
$20.14 $20.17 $19.66 27814
Last updated 12.16pm 03/07/2024 ?
NEU (ASX) Chart

Top Stories

Sun Silver gets that drill to thrill feeling from high grade hits at Maverick Spring

Sun Silver executive director Gerard O'Donovan discusses a 6,216 grams Fort Intercept at the Maverick Spring Silver Project from historical data and drill assessments.
Ark Mines inks 1.5Bt Exploration Target for Sandy Mitchell REE play including NdPr; PFS due in Q4 Ark Mines has published an Exploration Target for its Sandy Mitchell REE project of up to 1.5B tonnes @ up to 1490ppm monazite equivalent
Sun Silver to kick off drilling next week at 292Moz Maverick Springs silver-gold project  The company has locked in a drilling contractor to fire up a Reverse Circulation (RC) drill rig at Maverick starting on 8th of July US time. 
Has uranium run out of steam? An update on nuclear markets & developments ahead in FY25 Uranium was one bright spot at the start of 2024, standing out against otherwise glum markets that defined 2023.
Amplia enrols new patients to progress testing for pancreatic cancer drug Amplia Therapeutics Ltd has enrolled a new group of patients to test the efficacy of its drug narmafotinib in treatment of pancreatic cancer.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.